From Wikipedia, the free encyclopedia
  (Redirected from Aptalis Pharma)
Jump to: navigation, search
Type Private
Industry Pharmaceutical
Headquarters United States
Key people Brenton L. Saunders, CEO of Forest Laboratories
Owners Forest Laboratories
Employees 875[1]
Website www.aptalispharma.com

Aptalis is a wholly owned subsidiary of Forest Laboratories that develops, manufactures, markets, and distributes a broad line of gastrointestinal (GI) and specialty products, primarily in North America and Europe. Aptalis has manufacturing sites in Canada, Italy, the US, and France.


Aptalis was formed in 2011 after the acquisition of Eurand Pharmaceuticals by Montreal-based Axcan Pharma.[2][3] Axcan's area of specialty was the treatment of gastrointestinal disorders. Formerly traded publicly on NASDAQ, Axcan was acquired by TPG Capital in 2008.[4] Eurand Pharmaceuticals was a producer and contract manufacturer of modified release or taste-masked pharmaceutical dosage forms. Eurand's former manufacturing facilities in Vandalia, Ohio and Milan, Italy continued to operate under the Aptalis name.

Both Axcan and Eurand produced and marketed versions of the drug pancrelipase, which is used in the treatment of symptoms related to cystic fibrosis.

In January 2014, Forest Laboratories announced that it had agreed to buy specialty pharmaceutical company Aptalis Holdings Inc. for $2.9 billion in cash.[5][6][6]


External links[edit]